First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Phase of Trial: Phase I/II
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Bladder cancer; Cervical cancer; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Genmab
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 20 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.
- 20 Feb 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History